Press release
Oncolytic Virus Cancer Therapy Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Oncolytic Virus Cancer Therapy Overview
Oncolytic virus (OV) cancer therapies are the virus based therapeutic strategies that infect and destroy cancer cells, and therefore act as an in situ cancer vaccine by releasing tumor-specific antigens. Viruses such as myxoma virus or reovirushave inherent selectivity to tumor cells, while being nonpathogenic to healthy human cells. On the other hand, other OVs, including adenovirus, herpes simplex virus type-1 (HSV-1), and vesicular stomatitis virus (VSV), have been genetically engineered to function as vectors to boost anti-tumor immune responses. The anti-tumor efficacies of these OVs have been evaluated in many preclinical and clinical studies as monotherapy and combination therapy.
"Oncolytic Virus Cancer Therapy Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Oncolytic Virus Cancer Therapy Market.
The Oncolytic Virus Cancer Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report: https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Oncolytic Virus Cancer Therapy treatment therapies with a considerable amount of success over the years. Oncolytic Virus Cancer Therapy Key players such as - DNAtrix, Nouscom, Astellas Pharma, Transgene, Istari Oncology, DNAtrix, Targovax, Oncolytics Biotech, CG Oncolgy, and others, are developing therapies for the Oncolytic Virus Cancer Therapy treatment
• Oncolytic Virus Cancer Therapy Emerging therapies such as - DNX 2440, NOUS PEV, ASP 9801, TG 6002, PVS-RIPO, DNX-2401, ONCOS 102, Pelareorep, CG0070, and others are expected to have a significant impact on the Oncolytic Virus Cancer Therapy market in the coming years.
• In October 2020 CG Oncology initiated a trial entitled as "A Phase 3 Study of CG0070 in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)". The trial will get completed on January 2024 with an enrollment of 110 participants.
• In September 2021 CG Oncology, Inc. announced a clinical trial collaboration to evaluate the safety and efficacy ofCG0070, an oncolytic immunotherapy, in combination with OPDIVO^® (nivolumab), Bristol Myers Squibb's anti-PD-1therapy, for the treatment of metastatic urothelial cancer in a Phase 1/2 clinical study.
• In November 2022, CG Oncology announced new updated data from its global Phase 2 study (CORE1) of CG0070 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab), for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG).
Oncolytic Virus Cancer Therapy Pipeline Therapeutics Assessment
• Oncolytic Virus Cancer Therapy Assessment by Product Type
• Oncolytic Virus Cancer Therapy By Stage and Product Type
• Oncolytic Virus Cancer Therapy Assessment by Route of Administration
• Oncolytic Virus Cancer Therapy By Stage and Route of Administration
• Oncolytic Virus Cancer Therapy Assessment by Molecule Type
• Oncolytic Virus Cancer Therapy by Stage and Molecule Type
DelveInsight's Oncolytic Virus Cancer Therapy Report covers around 125+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Oncolytic Virus Cancer Therapy Drugs Under Different Phases of Clinical Development Include:
• DNX 2440: DNAtrix
• NOUS PEV: Nouscom
• ASP 9801:Astellas Pharma
• TG 6002 : Transgene
• PVS-RIPO: Istari Oncology
• DNX-2401: DNAtrix
• ONCOS 102: Targovax
• Pelareorep: Oncolytics Biotech
• CG0070: CG Oncolgy
Get a Free Sample PDF Report to know more about Oncolytic Virus Cancer Therapy Pipeline Assessment- https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Oncolytic Virus Cancer Therapy Pipeline Analysis:
The Oncolytic Virus Cancer Therapy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Oncolytic Virus Cancer Therapy treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy Treatment.
• Oncolytic Virus Cancer Therapy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Oncolytic Virus Cancer Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oncolytic Virus Cancer Therapy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Oncolytic Virus Cancer Therapy product details are provided in the report. Download the Oncolytic Virus Cancer Therapy pipeline report to learn more about the emerging Oncolytic Virus Cancer Therapy therapies at:
https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Oncolytic Virus Cancer Therapy Pipeline Market Drivers
• Increase in the number of patients with cancers
• Rising need for advanced and effective cancer therapeutics for improved quality of life
Oncolytic Virus Cancer Therapy Pipeline Market Barriers
• Lack of development, scale up and commercialization resources available to developers
• Lack of awareness about the new class of anticancer immunotherapy
Scope of Oncolytic Virus Cancer Therapy Pipeline Drug Insight
• Coverage: Global
• Key Oncolytic Virus Cancer Therapy Companies: DNAtrix, Nouscom, Astellas Pharma, Transgene, Istari Oncology, DNAtrix, Targovax, Oncolytics Biotech, CG Oncolgy, and others
• Key Oncolytic Virus Cancer Therapy Therapies: DNX 2440, NOUS PEV, ASP 9801, TG 6002, PVS-RIPO, DNX-2401, ONCOS 102, Pelareorep, CG0070, and others
• Oncolytic Virus Cancer Therapy Therapeutic Assessment: Oncolytic Virus Cancer Therapy current marketed and Oncolytic Virus Cancer Therapy emerging therapies
• Oncolytic Virus Cancer Therapy Market Dynamics: Oncolytic Virus Cancer Therapy market drivers and Oncolytic Virus Cancer Therapy market barriers
Request for Sample PDF Report for Oncolytic Virus Cancer Therapy Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Oncolytic Virus Cancer Therapy Report Introduction
2 Oncolytic Virus Cancer Therapy Executive Summary
3 Oncolytic Virus Cancer Therapy Overview
4 Oncolytic Virus Cancer Therapy- Analytical Perspective In-depth Commercial Assessment
5 Oncolytic Virus Cancer Therapy Pipeline Therapeutics
6 Oncolytic Virus Cancer Therapy Late Stage Products (Phase II/III)
7 Oncolytic Virus Cancer Therapy Mid Stage Products (Phase II)
8 Oncolytic Virus Cancer Therapy Early Stage Products (Phase I)
9 Oncolytic Virus Cancer Therapy Preclinical Stage Products
10 Oncolytic Virus Cancer Therapy Therapeutics Assessment
11 Oncolytic Virus Cancer Therapy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Oncolytic Virus Cancer Therapy Key Companies
14 Oncolytic Virus Cancer Therapy Key Products
15 Oncolytic Virus Cancer Therapy Unmet Needs
16 Oncolytic Virus Cancer Therapy Market Drivers and Barriers
17 Oncolytic Virus Cancer Therapy Future Perspectives and Conclusion
18 Oncolytic Virus Cancer Therapy Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Oncolytic Virus Cancer Therapy drugs and therapies- https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Oncolytic Virus Cancer Therapy Market https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Oncolytic Virus Cancer Therapy-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Oncolytic Virus Cancer Therapy Epidemiology https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Oncolytic Virus Cancer Therapy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oncolytic Virus Cancer Therapy Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2861095 • Views: …
More Releases from DelveInsight Business Research
Alpha-1 Antitrypsin Deficiency Pipeline 2025: FDA Updates, Therapy Innovations, …
Alpha-1 Antitrypsin Deficiency pipeline constitutes 12+ key companies continuously working towards developing 12+ Alpha-1 Antitrypsin Deficiency treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha-1 Antitrypsin Deficiency Market.
The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial…
Invasive Pneumococcal Disease Pipeline 2025: MOA, ROA, and Clinical Trial Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Invasive Pneumococcal Disease pipeline constitutes key companies continuously working towards developing Invasive Pneumococcal Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Invasive Pneumococcal Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Invasive Pneumococcal Disease Market.
…
WHIM Syndrome Market Expected to Gain Momentum Through 2034, According to DelveI …
DelveInsight's "WHIM Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the WHIM Syndrome, historical and forecasted epidemiology as well as the WHIM Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the WHIM Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; WHIM Syndrome Market Forecast
https://www.delveinsight.com/sample-request/whim-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Chronic Inflammatory Demyelinating Polyneuropathy Market Trends Point to Steady …
DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy, historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Inflammatory Demyelinating Polyneuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click…
More Releases for Oncolytic
Prominent Oncolytic Virus Therapy Market Trend for 2025: Accelerating Oncolytic …
Which drivers are expected to have the greatest impact on the over the oncolytic virus therapy market's growth?
The rise in cancer incidences is likely to fuel the expansion of the oncolytic virus therapy market. Oncolytic virus therapy is gaining traction as an appealing approach to treating cancer- a collection of diseases marked by abnormal cell growth and proliferation. This therapeutic strategy effectively targets and eliminates cancer cells, while also triggering…
Enhancing the Immune Response with Oncolytic Virus Therapy
Oncolytic virus therapy is revolutionizing cancer treatment by harnessing the unique characteristics of viruses to specifically target and destroy cancer cells. This cutting-edge approach represents a significant advancement in cancer care, offering renewed hope for patients with different types of cancer.
Download Report:
https://www.kuickresearch.com/report-oncolytic-virus-immunotherapy-market-oncolytic-virus-therapy-market-oncolytic-virus-fda-approved-oncolytic-virus-clinical-trilas
The essence of oncolytic virus therapy is based on genetically modified viruses that can selectively attack and kill cancer cells while leaving healthy tissue unharmed. These engineered viruses take…
Creative Biolabs Unleashes Solutions to Validate Oncolytic Virotherapy
Creative Biolabs introduces safety and efficacy validation strategies for oncolytic virotherapy.
New York, USA - June 17, 2024 - Oncolytic virotherapy appears as a new paradigm in cancer immunotherapy that enrolls specifically engineered viruses to selectively infect and kill cancer cells, some of which have marched into clinical trials, like adenoviruses, HSV, reovirus, vaccinia virus, and measles. With so many other candidates still on their preclinical journey, the requests to validate…
Oncolytic Virus Competitive Landscape 2023 (Updated)
DelveInsight's, "Oncolytic Virus Competitive Landscape 2023" report provides comprehensive insights about 150+ Oncolytic Virus Companies and 175+ drugs in the Oncolytic Virus Competitive landscape. It covers the Oncolytic Virus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Oncolytic Virus Competitive Landscape Report
• DelveInsight's Oncolytic Virus report depicts a robust space with 150+ Oncolytic…
Oncolytic Virus Therapy Market Oncolytic Virus Therapy Clinical Pipeline Report …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Oncolytic Virus
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics
Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting
Mechanism…
Global Oncolytic Virus Therapy Report Highlight Market Opportunity & Insight On …
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic…
